Status:

COMPLETED

TIPS Plus Transvenous Obliteration for Gastric Varices

Lead Sponsor:

University of Illinois at Chicago

Conditions:

Cirrhosis, Liver

Hypertension, Portal

Eligibility:

All Genders

18+ years

Brief Summary

Variceal hemorrhage (VH) from gastric varices (GVs) results in significant morbidity and mortality among patients with liver cirrhosis. In cases of acute bleeding, refractory bleeding, or high risk GV...

Detailed Description

Liver cirrhosis-or scarring of the liver-occurs with a worldwide prevalence approximating 4.5-9.5%, affecting hundreds of millions of people. Cirrhosis results in 2% of all global mortality, approxima...

Eligibility Criteria

Inclusion

  • Aged ≥ 18 years
  • Ability to provide written consent
  • Endoscopically proven acute or recurrent VH from GVs, or high risk GVs

Exclusion

  • Prior indwelling TIPS
  • Prior endovascular obliteration procedure
  • Elevated heart pressures (left or right)
  • Heart failure or severe valvular insufficiency
  • Severe pulmonary hypertension
  • Rapidly progressive liver failure
  • Severe or uncontrolled hepatic encephalopathy
  • Uncontrolled systemic infection or sepsis
  • Unrelieved biliary obstruction
  • Polycystic liver disease
  • Extensive primary or metastatic hepatic malignancy
  • Severe uncontrolled coagulopathy
  • Pregnancy

Key Trial Info

Start Date :

April 4 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 18 2024

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT04044248

Start Date

April 4 2019

End Date

June 18 2024

Last Update

November 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Illinois at Chicago

Chicago, Illinois, United States, 60612